
Can ctDNA help inform on the suitability of auto-SCT in patients with DLBCL?
This is the second episode in a series of podcasts following the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, on the topic of circulating tumor DNA (ctDNA) in the management of lymphoma. The Lymphoma hub asked Reid Merryman, Dana-Farber Cancer Institute, Boston, US, Can circulating tumor DNA (ctDNA) help inform on the suitability of autologous stem cell transplantation (auto-SCT) in patients with diffuse large B-cell lymphoma (DLBCL)?
Merryman firstly outlines a strategy for using ctDNA as a prognostic biomarker in patients with DLBCL undergoing auto-STC. Merryman…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.